Stock Price

TaseIcon BVXV.TA (Ag)
BiondVax to voluntarily delist from TASE in January, 2018. Click here for details and investor FAQ.

NasdaqIcon32x32 BVXV (US$)
Stock Quote: Nasdaq.com
One US ADS = 40 Tel Aviv shares

IR Kit

Presentation

IR Contact

Josh Phillipson
Business Development

+972 8 930 2529

Company Profile

BiondVax is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains. BiondVax’s technology utilizes a unique, proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.

Recent News